Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused

This project analyzes the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, and explored the factors influencing TSH inhibitory treatment efficacy. It further explores whether patients with diO2-Thr92ALA genotype or DIO2 Orfa-Gly3ASP genotype should choose T4+T3 treatment, and the effect of different treatment options on the quality life of patients.

Study Overview

• Status: Recruiting
• Conditions: Hypothyroidism; Thyroid Cancer, Papillary
• Intervention / Treatment: Drug: L-T4; Drug: L-T4+T3 (thyroid tablet)

Detailed Description

Object: To explore the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, And figure out if it is better for patients with diO2-Thr92ALA genotype or DIO2 Orfa-Gly3ASP genotype to choose T4+T3 treatment,

Design:

Part I: Analysis of the correlation between DIO2 genotype and TSH inhibitory treatment effect:

1. In accordance with inclusion and exclusion criteria; A total of 100 patients undergoing total thyroidectomy for thyroid cancer and 100 patients receiving 131 iodine treatment after total thyroidectomy will be included in our hospital from October 2021 to October 2022. All the patients signed informed consent

2. Detection of basic condition:

   The included patients were recorded with height, weight, BMI, routine biochemistry, homocysteine, thyroid function, thyroid peroxidase antibodies, thyroglobulin, thyroid globulin,

3. Genotype detection of DIO2 gene RS225014 and RS12885300 loci were tested for all the patients.

4. Regular L-T4 treatment and drug dose adjustment:

   Patients included in the study were treated with L-T4 daily and the drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH inhibition target was achieved as far as possible. After 3 months' treatment. The data of height, weight, BMI, routine biochemistry, thyroid function, thyroid peroxidase antibodies, thyroglobulin, thyroid globulin were tested again. SF-36 health survey were tested to evaluated the living quality.

5. The effect of genotype and allele frequency on TSH inhibitory treatment was analyzed.

Part II: Compare the effects of single L-T4 treatment and L-T4+T3 on TSH inhibitory treatment and side effects

1. L-t4 treatment vs T4+T3 treatment:

   Through the analysis of the first step, patients with refractory hypothyroidism whose FT4 dose reached 1.9ug/kg/d and TSH inhibition treatment failed to reach the standard were screened out, and these patients were randomly divided into L-T4 treatment group and L-T4+T3 treatment group. The patients were followed up for half a year, and the drug dose was adjusted every month to make TSH inhibition treatment target as far as possible.

2. After half a year of treatment, the height, weight, BMI, routine biochemistry, thyroid function, thyroid peroxidase antibody, thyroglobulin, thyroglobulin antibody, were examined again. All patients were reevaluated SF-36 health survey.
3. Statistical analysis was made of the effects of different treatment methods on TSH inhibition therapy and the effects on patients' quality of life,

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Yanling Huang, principal; Phone Number: +8615880277690; Email: xmhuangyanling@xmu.edu.cn
• Study Contact Backup: Name: Junhan Chen, assistant; Phone Number: 15280406008; Email: 116569145@qq.com

Study Locations

• China
  • Fujian
    • Xiamen, Fujian, China, 361004
      • Recruiting
      • Yan Ling
      • Contact: yan ling; Phone Number: 13850087896; Email: 1543820053@qq.com
      • Contact: Junhan Chen; Phone Number: 15280406008; Email: 116569145@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18-65
2. Patients with Hypothyroidism after total thyroidectomy for papillary thyroid carcinoma
3. Patients were informed of the study and voluntarily willing to participate.

Exclusion Criteria:

1. Having depression or other mental illness
2. Taking drugs that interfere with thyroid hormone absorption for other chronic diseases
3. impaired liver function, defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
4. impaired renal function ,eGFR: <45 mL/min (calculated by MDRD formula)
5. Recent Cardiovascular Events in a patient:

(1)Acute Coronary Syndrome (ACS) within 2 months prior to enrolment (2).Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment (3)Acute Stroke or TIA within two months prior to enrolment (4)Less than two months post coronary artery revascularization 6. Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.

7. Pregnant or breastfeeding women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: L-T4 therapy group; Patients with refractory hypothyroidism still receive L-T4 therapy as usual.	Drug: L-T4; Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Experimental: L-T4+T3 therapy group; Patients with refractory hypothyroidism receive L-T4+T3 therapy	Drug: L-T4+T3 (thyroid tablet); Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
TSH suppression	The TSH level can reach the aim of the TSH suppresion therapy	Up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
quality life evalutaion	evaluate the quality life of the patients with SF-36 survey.	Up to 6 months

Collaborators and Investigators

• Sponsor: Zhongshan Hospital Xiamen University
• Investigators: Study Director: Yilin Zhao, Zhongshan Hospital Xiamen University

Study record dates

Study Major Dates

• Study Start (Actual): October 18, 2021
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): September 1, 2022

Study Registration Dates

• First Submitted: February 9, 2022
• First Submitted That Met QC Criteria: February 9, 2022
• First Posted (Actual): February 18, 2022

Study Record Updates

• Last Update Posted (Actual): February 18, 2022
• Last Update Submitted That Met QC Criteria: February 9, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: type 2 deiodinase, TSH suppression
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Endocrine System Diseases; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Hypothyroidism; Thyroid Diseases; Thyroid Neoplasms; Thyroid Cancer, Papillary
• Other Study ID Numbers: 2021-123

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No